Navigation Links
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
Date:9/24/2009

ody in development for the potential treatment of advanced ovarian cancer. In vitro, farletuzumab appears to have antiproliferative and cytotoxic activities in tumor cells that over express FRA.

A randomized global Phase III study to test farletuzumab in combination with platinum and taxane (P/T) in platinum-sensitive ovarian cancer subjects is currently underway. For more information about the Phase III trial, please visit www.far-trials.com or www.clinicaltrials.gov.

About Morphotek

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.

Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies
'/>"/>

SOURCE Morphotek(R), Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
2. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
3. ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented
4. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
5. New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal
6. QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
7. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009
8. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
9. Late Breaking Clinical Trials Presented at HFSA 13th Annual Scientific Meeting
10. Study on PLC Systems TMR Therapy With Stem Cells Presented at ESC 2009
11. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 Isis ... that it has earned a $4 million milestone ... ) associated with the initiation of a Phase ... multi-drug resistant (MDR), gram-negative bacterial infections.  The Phase ... to evaluate the efficacy and safety of plazomicin ...
(Date:9/17/2014)... Sutro Biopharma, a biopharmaceutical company developing antibody ... of Merck KGaA, Darmstadt, Germany , ... United States and Canada ... develop antibody drug conjugates (ADCs). ADCs are composed of ... is thought to specifically target and deliver the cytotoxic ...
(Date:9/17/2014)... , Sept. 17, 2014  Fortune Oil and Gas, ... its name to Manzo Pharmaceuticals, Inc. with the symbol ... effect today, September 17, 2014. Also taking effect today ... The approval is a pivotal event in the company,s ... Manzo explained, "We could not proceed with the plan ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3
(Date:9/17/2014)... for the very healthy. Astronauts are selected for ... psychological standards to prepare them for any unknown ... average people can now fly for enjoyment. The ... about what medical conditions or diseases should be ... most medical conditions have never been studied for ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Functional Fitness ... Ritchie and Dr. Cody Sipe that is helping middle-aged adults ... and longevity has caught the attention of Shane Michaels, prompting ... in their 50s, 60s, or even 70s what would be ... on a day-to-day basis, they would probably answer that the ...
(Date:9/17/2014)... -- Social networking sites can help people lose weight, ... are obese, sites like Twitter and Facebook can be ... as well as peers, researchers found. "One advantage ... it offers the potential to be much more cost ... traditional approaches," the study,s lead author, Dr. Hutan Ashrafian, ...
(Date:9/17/2014)... 2014 The Oliver Law Group P.C. ... caused by Non-Sterile Other-Sonic Ultrasound Transmission Gel to ... options for legal recourse. Other-Sonic ultrasound gel was recalled ... March 2012, after the product was linked to a ... Hospital in Royal Oak, Michigan . While victims of ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Catalent ... delivery technologies and development solutions for drugs, biologics ... of OptiPact™, an integrated service and technology offer ... and provided from the company’s 450,000 sq. ft. ... Catalent’s ability to integrate optimal formulation, development, analytical ...
Breaking Medicine News(10 mins):Health News:Space: The final frontier… open to the public 2Health News:Functional Fitness Solution: Review Exposes Dr. Dan Ritchie and Dr. Cody Sipe’s Guide to Everyday Fitness for Longevity 2Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:New OptiPact™ Technology Introduced by Catalent 2
... ATLANTA, Aug. 11 MinuteClinic, the pioneer and largest provider ... a first-of-its kind rapid conjunctivitis (pink-eye) test at its 23 locations ... test is a pilot project conducted in partnership with Rapid Pathogen ... at a future date in its clinic locations in 25 states. ...
... PITTSBURGH, Aug. 11 Foundation Radiology ... headquartered in Pittsburgh, is pleased to announce its exclusive imaging ... , Uniontown Hospital, a 224-bed hospital, has ... of Fayette County and surrounding areas for over 100 years. ...
... , SOMERSET, N.J., Aug. 11 ... healthcare and administrative staffing services, will announce its third quarter financial results ... before the market opens. TeamStaff will host a conference call for ... Interested parties may participate in the call by dialing (877) ...
... , , , SAN ... CXM ) today reported its financial results for its second ... future outlook. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ... since first quarter 2009 financial report and highlights included (1) ...
... , , NEW YORK, Aug. ... a contract by ValueOptions(R), a behavioral health care company headquartered ... services for ValueOptions(R) at risk Plans, which cover approximately 1.5 ... Medicaid members that have other healthcare coverage, and recover overpayments ...
... MIAMI, Aug. 11 ECHealthInsurance.com a Florida based health ... month to help Floridians. According to Vice President of Marketing ... August is the only month every year that is open ... seasonality spikes of Florida our summer is much slower as ...
Cached Medicine News:Health News:MinuteClinic Offers New Rapid Pink-Eye Test; Detects Viral Conjunctivitis Infections in Minutes 2Health News:MinuteClinic Offers New Rapid Pink-Eye Test; Detects Viral Conjunctivitis Infections in Minutes 3Health News:Foundation Radiology Group Signs Exclusive Contract With Uniontown Hospital 2Health News:TeamStaff, Inc. To Announce Third Quarter Results 2Health News:TeamStaff, Inc. To Announce Third Quarter Results 3Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 2Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 3Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 4Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 5Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 6Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 7Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 8Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 9Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 10Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 11Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 12Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 13Health News:ValueOptions(R) Awards Coordination of Benefits and Overpayment Services Contract to HMS 2Health News:Florida Health Insurance Brokerage to Donate Month of August to Help Residents of Florida 2
... androgen secreted into the blood. In males, ... of the testes; in females ca. 50% ... of androstenedione, ca. 25% from the ovary ... The Testosterone ELISA KIT is based on ...
Microalbumin EIA Lipid / Protein Quantification 024-IDC-12...
Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6...
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Medicine Products: